Biophytis (BPTSY) Competitors $2.00 0.00 (0.00%) As of 08/22/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock BPTSY vs. LIPO, SPRC, GLMD, CANF, ADTX, ADXS, UPC, AIM, SXTP, and AKANShould you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Lipella Pharmaceuticals (LIPO), SciSparc (SPRC), Galmed Pharmaceuticals (GLMD), Can-Fite BioPharma (CANF), Aditxt (ADTX), Ayala Pharmaceuticals (ADXS), Universe Pharmaceuticals (UPC), AIM ImmunoTech (AIM), 60 Degrees Pharmaceuticals (SXTP), and Akanda (AKAN). These companies are all part of the "pharmaceutical products" industry. Biophytis vs. Its Competitors Lipella Pharmaceuticals SciSparc Galmed Pharmaceuticals Can-Fite BioPharma Aditxt Ayala Pharmaceuticals Universe Pharmaceuticals AIM ImmunoTech 60 Degrees Pharmaceuticals Akanda Lipella Pharmaceuticals (NASDAQ:LIPO) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability. Do institutionals & insiders believe in LIPO or BPTSY? 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of Biophytis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer LIPO or BPTSY? In the previous week, Biophytis had 1 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 1 mentions for Biophytis and 0 mentions for Lipella Pharmaceuticals. Biophytis' average media sentiment score of 0.98 beat Lipella Pharmaceuticals' score of 0.00 indicating that Biophytis is being referred to more favorably in the news media. Company Overall Sentiment Lipella Pharmaceuticals Neutral Biophytis Positive Which has more risk and volatility, LIPO or BPTSY? Lipella Pharmaceuticals has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Comparatively, Biophytis has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Is LIPO or BPTSY more profitable? Biophytis has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Biophytis' return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lipella Pharmaceuticals-988.83% -224.08% -172.88% Biophytis N/A N/A N/A Which has stronger valuation & earnings, LIPO or BPTSY? Lipella Pharmaceuticals has higher revenue and earnings than Biophytis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipella Pharmaceuticals$536.36K5.08-$5.02M-$3.43-0.17BiophytisN/AN/A-$18.43MN/AN/A SummaryBiophytis beats Lipella Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get Biophytis News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTSY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTSY vs. The Competition Export to ExcelMetricBiophytisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$702K$833.53M$5.82B$9.77BDividend YieldN/A4.84%4.40%4.06%P/E RatioN/A1.1831.3026.05Price / SalesN/A152.90433.43108.36Price / CashN/A19.5638.0259.36Price / Book-0.126.649.536.60Net Income-$18.43M-$4.94M$3.26B$265.65M7 Day PerformanceN/A1.85%2.13%1.99%1 Month PerformanceN/A3.06%3.21%0.45%1 Year Performance-69.97%12.25%30.18%18.87% Biophytis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTSYBiophytisN/A$2.00flatN/A-70.0%$702KN/A0.0030LIPOLipella PharmaceuticalsN/A$0.60+1.1%N/A-85.8%$2.64M$536.36K-0.154SPRCSciSparcN/A$4.17-7.5%N/A-39.9%$2.41M$1.31M0.004High Trading VolumeGLMDGalmed Pharmaceuticals1.0771 of 5 stars$1.43+0.4%N/A-58.7%$2.36MN/A-0.0920Upcoming EarningsCANFCan-Fite BioPharma2.1172 of 5 stars$0.66+3.5%$14.00+2,030.9%-71.9%$2.33M$674K-0.378Negative NewsADTXAditxt0.3539 of 5 stars$1.04-4.6%N/A-100.0%$2.31M$130K0.0060News CoverageGap UpADXSAyala PharmaceuticalsN/A$0.05flatN/A+165.0%$2.26M$3.24M-0.0120UPCUniverse PharmaceuticalsN/A$3.50+2.2%N/A-99.8%$1.97M$19.29M0.00220Gap UpAIMAIM ImmunoTech1.1756 of 5 stars$2.48-1.2%$275.00+10,988.7%-92.7%$1.90M$121K-5.2820News CoverageSXTP60 Degrees Pharmaceuticals2.3685 of 5 stars$1.27-0.8%$7.00+451.2%-86.1%$1.89M$641.41K-0.033News CoverageShort Interest ↓AKANAkanda1.1193 of 5 stars$1.33+0.4%N/A-53.3%$1.88M$840K0.00110News CoverageShort Interest ↑ Related Companies and Tools Related Companies Lipella Pharmaceuticals Alternatives SciSparc Alternatives Galmed Pharmaceuticals Alternatives Can-Fite BioPharma Alternatives Aditxt Alternatives Ayala Pharmaceuticals Alternatives Universe Pharmaceuticals Alternatives AIM ImmunoTech Alternatives 60 Degrees Pharmaceuticals Alternatives Akanda Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTSY) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biophytis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biophytis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access